SSA
HUMA icon

Schonfeld Strategic Advisors’s Humacyte HUMA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126K Buy
+161,639
New +$150K ﹤0.01% 2271
2021
Q2 		– Sell
-16,481
Closed -$178K – 2100
2021
Q1 		$178K Buy
+16,481
New +$180K ﹤0.01% 1545

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Schonfeld Strategic Advisors's HUMA Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Humacyte (HUMA) in Q2 2026: 161,639 shares worth $126K. The stake represents ﹤0.01% of the portfolio and ranks #2271 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in HUMA as recently as Q1 2021.

Schonfeld Strategic Advisors first reported a position in HUMA in Q1 2021 and has held it in 2 quarters since. The position peaked at $178K in Q1 2021. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Schonfeld Strategic Advisors held 161,639 shares of Humacyte worth $126K as of Q2 2026.
  • Humacyte was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Humacyte made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2271 holding.
  • Schonfeld Strategic Advisors first reported a position in Humacyte in Q1 2021 and has held it in 2 quarters since.
  • Schonfeld Strategic Advisors's Humacyte position peaked at $178K in Q1 2021.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.